Antibody responses to α-Gal in African children vary with age and site and are associated with malaria protection

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Aguilar, Ruth ^a   Ubillos, Itziar ^a   Vidal, Marta ^a   Balanza, Núria ^a   Crespo, Núria ^a   Jiménez, Alfons ^a,b   Nhabomba, Augusto ^c   Jairoce, Chenjerai ^c   Dosoo, David ^d   Gyan, Ben ^d   Ayestaran, Aintzane ^a   Sanz, Hèctor ^a   Campo, Joseph J ^a   Gómez Pérez, Gloria P ^a   Izquierdo, Luis ^a   Dobaño, Carlota ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Manhiça Health Research Center   (Mozambique)

^d Kintampo Health Research Center Ghana   (Ghana)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; GALACTOSE; IMMUNOGLOBULIN CLASS; MALARIA VACCINE; PARASITE ANTIGEN; PROTOZOON ANTIBODY;

AFRICA; AGE; ANTIBODY PRODUCTION; BLACK PERSON; FEMALE; GENETICS; GHANA; HUMAN; IMMUNOLOGY; INFANT; MALARIA; MALARIA FALCIPARUM; MALE; MOZAMBIQUE; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD;

AFRICA; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; ANTIBODIES; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; CHILD, PRESCHOOL; FEMALE; GALACTOSE; GHANA; HUMANS; IMMUNOGLOBULIN ISOTYPES; INFANT; MALARIA; MALARIA VACCINES; MALARIA, FALCIPARUM; MALE; MOZAMBIQUE; PLASMODIUM FALCIPARUM;

EID: 85049512403     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-28325-w     Document Type: Article

References (63)

1. Cobb, B. A. & Kasper, D. L. Coming of age: carbohydrates and immunity. Eur J Immunol 35, 352-356 (2005).
2. Beuvery, E. C., van Rossum, F. & Nagel, J. Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates. Infect Immun 37, 15-22 (1982).
3. Barrett, D. J., Ammann, A. J., Stenmark, S. & Wara, D. W. Immunoglobulin G and M antibodies to pneumococcal polysaccharides detected by enzyme-linked immunosorbent assay. Infect Immun 27, 411-417 (1980).
4. Grundner, C. et al. Factors limiting the immunogenicity of HIV-1gp120 envelope glycoproteins. Virology 330, 233-248 (2004).
5. Godfrey, D. I. & Kronenberg, M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Invest 114, 1379-1388 (2004).
6. Tzianabos, A. O. et al. T cells activated by zwitterionic molecules prevent abscesses induced by pathogenic bacteria. J Biol Chem 275, 6733-6740 (2000).
7. Trotter, C. L. & Ramsay, M. E. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev 31, 101-107 (2007).
8. Rodrigues, J. A. et al. Parasite Glycobiology: A Bittersweet Symphony. PLoS Pathog 11, e1005169 (2015).
9. Naik, R. S., Krishnegowda, G., Ockenhouse, C. F. & Gowda, D. C. Naturally elicited antibodies to glycosylphosphatidylinositols (GPIs) of Plasmodium falciparum require intact GPI structures for binding and are directed primarily against the conserved glycan moiety. Infect Immun 74, 1412-1415 (2006).
10. Cova, M., Rodrigues, J. A., Smith, T. K. & Izquierdo, L. Sugar activation and glycosylation in Plasmodium. Malar J 14, 427 (2015).
11. Sanz, S. et al. Biosynthesis of GDP-fucose and other sugar nucleotides in the blood stages of Plasmodium falciparum. J Biol Chem 288, 16506-16517 (2013).
12. Lopez-Gutierrez, B., Dinglasan, R. R. & Izquierdo, L. Sugar nucleotide quantification by liquid chromatography tandem mass spectrometry reveals a distinct profile in Plasmodium falciparum sexual stage parasites. Biochem J 474, 897-905 (2017).
13. Bushkin, G. G. et al. Suggestive evidence for Darwinian Selection against asparagine-linked glycans of Plasmodium falciparum and Toxoplasma gondii. Eukaryot Cell 9, 228-241 (2010).
14. Swearingen, K. E. et al. Interrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics. PLoS Pathog 12, e1005606 (2016).
15. Sanz, S. et al. The disruption of GDP-fucose de novo biosynthesis suggests the presence of a novel fucose-containing glycoconjugate in Plasmodium asexual blood stages. Sci Rep 6, 37230 (2016).
16. Agnandji, S. T. et al. A phase 3 trial of RTS, S/AS01 malaria vaccine in African infants. N Engl J Med 367, 2284-2295 (2012).
17. Yilmaz, B. et al. Gut microbiota elicits a protective immune response against malaria transmission. Cell 159, 1277-1289 (2014).
18. Ramasamy, R. & Reese, R. T. Terminal galactose residues and the antigenicity of Plasmodium falciparum glycoproteins. Mol Biochem Parasitol 19, 91-101 (1986).
19. Galili, U., Rachmilewitz, E. A., Peleg, A. & Flechner, I. A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J Exp Med 160, 1519-1531 (1984).
20. Galili, U. & Swanson, K. Gene sequences suggest inactivation of alpha-1, 3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci USA 88, 7401-7404 (1991).
21. Macher, B. A. & Galili, U. The Galalpha1, 3Galbeta1, 4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevance. Biochim Biophys Acta 1780, 75-88 (2008).
22. Galili, U., Mandrell, R. E., Hamadeh, R. M., Shohet, S. B. & Griffiss, J. M. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun 56, 1730-1737 (1988).
23. Avila, J. L., Rojas, M. & Galili, U. Immunogenic Gal alpha 1-3Gal carbohydrate epitopes are present on pathogenic American Trypanosoma and Leishmania. J Immunol 142, 2828-2834 (1989).
24. Almeida, I. C., Ferguson, M. A., Schenkman, S. & Travassos, L. R. Lytic anti-alpha-galactosyl antibodies from patients with chronic Chagas' disease recognize novel O-linked oligosaccharides on mucin-like glycosyl-phosphatidylinositol-anchored glycoproteins of Trypanosoma cruzi. Biochem J 304(Pt 3), 793-802 (1994).
25. Milani, S. R. & Travassos, L. R. Anti-alpha-galactosyl antibodies in chagasic patients. Possible biological significance. Braz J Med Biol Res 21, 1275-1286 (1988).
26. Bishop, J. R. & Gagneux, P. Evolution of carbohydrate antigens-microbial forces shaping host glycomes? Glycobiology 17, 23R-34R (2007).
27. Doenz, U., Nydegger, U. E., Kueng, A., Carrel, T. & Mohacsi, P. Anti-Galalpha1-3Gal IgM/IgG antibody levels in infants: do they have a clinical relevance in pediatric xenotransplantation? J Heart Lung Transplant 19, 1108-1113 (2000).
28. Hamanova, M., Chmelikova, M., Nentwich, I., Thon, V. & Lokaj, J. Anti-Gal IgM, IgA and IgG natural antibodies in childhood. Immunol Lett 164, 40-43 (2015).
29. Cabrera-Rubio, R., Mira-Pascual, L., Mira, A. & Collado, M. C. Impact of mode of delivery on the milk microbiota composition of healthy women. J Dev Orig Health Dis 7, 54-60 (2016).
30. Kumar, H. et al. Distinct Patterns in Human Milk Microbiota and Fatty Acid Profiles Across Specific Geographic Locations. Front Microbiol 7, 1619 (2016).
31. Khodayar-Pardo, P., Mira-Pascual, L., Collado, M. C. & Martinez-Costa, C. Impact of lactation stage, gestational age and mode of delivery on breast milk microbiota. J Perinatol 34, 599-605 (2014).
32. Gomez-Gallego, C. et al. Breast Milk Polyamines and Microbiota Interactions: Impact of Mode of Delivery and Geographical Location. Ann Nutr Metab 70, 184-190 (2017).
33. Parker, A. R., Allen, S. & Harding, S. Concentration of anti-pneumococcal capsular polysaccharide IgM, IgG and IgA specific antibodies in adult blood donors. Pract Lab Med 5, 1-5 (2016).
34. Takeuchi, Y. et al. Sensitization of cells and retroviruses to human serum by (alpha 1-3) galactosyltransferase. Nature 379, 85-88 (1996).
35. Cunnington, A. J. & Riley, E. M. Suppression of vaccine responses by malaria: insignificant or overlooked? Expert Rev Vaccines 9, 409-429 (2010).
36. Timens, W., Boes, A., Rozeboom-Uiterwijk, T. & Poppema, S. Immaturity of the human splenic marginal zone in infancy. Possible contribution to the deficient infant immune response. J Immunol 143, 3200-3206 (1989).
37. Cerutti, A., Cols, M. & Puga, I. Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes. Nat Rev Immunol 13, 118-132 (2013).
38. Urban, B. C. et al. Fatal Plasmodium falciparum malaria causes specific patterns of splenic architectural disorganization. Infect Immun 73, 1986-1994 (2005).
39. Bockstal, V., Geurts, N. & Magez, S. Acute Disruption of Bone Marrow B Lymphopoiesis and Apoptosis of Transitional and Marginal Zone B Cells in the Spleen following a Blood-Stage Plasmodium chabaudi Infection in Mice. J Parasitol Res 2011, 534697 (2011).
40. Requena, P. et al. Pregnancy and malaria exposure are associated with changes in the B cell pool and in plasma eotaxin levels. J Immunol 193, 2971-2983 (2014).
41. Ubillos, I. et al. Chronic Exposure to Malaria Is Associated with Inhibitory and Activation Markers on Atypical Memory B Cells and Marginal Zone-Like B Cells. Front Immunol 8, 966 (2017).
42. Asito, A. S. et al. Suppression of circulating IgD+ CD27+ memory B cells in infants living in a malaria-endemic region of Kenya. Malar J 10, 362 (2011).
43. Gomez-Perez, G. P., van Bruggen, R., Grobusch, M. P. & Dobano, C. Plasmodium falciparum malaria and invasive bacterial coinfection in young African children: the dysfunctional spleen hypothesis. Malar J 13, 335 (2014).
44. Edwards, K. M. Maternal antibodies and infant immune responses to vaccines. Vaccine 33, 6469-6472 (2015).
45. Cabezas-Cruz, A. et al. Effect of blood type on anti-alpha-Gal immunity and the incidence of infectious diseases. Exp Mol Med 49, e301 (2017).
46. Aribot, G. et al. Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). Am J Trop Med Hyg 54, 449-457 (1996).
47. Metzger, W. G. et al. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol 25, 307-312 (2003).
48. Nebie, I. et al. Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 76, 759-766 (2008).
49. Shi, Y. P. et al. Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun 64, 2716-2723 (1996).
50. Soe, S., Theisen, M., Roussilhon, C., Aye, K. S. & Druilhe, P. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72, 247-252 (2004).
51. Boctor, F. N. & Peter, J. B. IgG subclasses in human chronic schistosomiasis: over-production of schistosome-specific and nonspecific IgG4. Clin Exp Immunol 82, 574-578 (1990).
52. Caulfield, J. P., Cianci, C. M., McDiarmid, S. S., Suyemitsu, T. & Schmid, K. Ultrastructure, carbohydrate, and amino acid analysis of two preparations of the cercarial glycocalyx of Schistosoma mansoni. J Parasitol 73, 514-522 (1987).
53. Hagan, P., Blumenthal, U. J., Dunn, D., Simpson, A. J. & Wilkins, H. A. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 349, 243-245 (1991).
54. James, L. K. & Till, S. J. Potential Mechanisms for IgG4 Inhibition of Immediate Hypersensitivity Reactions. Curr Allergy Asthma Rep 16, 23 (2016).
55. Santos, A. F. et al. IgG4 inhibits peanut-induced basophil and mast cell activation in peanut-tolerant children sensitized to peanut major allergens. J Allergy Clin Immunol 135, 1249-1256 (2015).
56. Church, J. & Maitland, K. Invasive bacterial co-infection in African children with Plasmodium falciparum malaria: a systematic review. BMC Med 12, 31 (2014).
57. Bassat, Q. et al. Severe malaria and concomitant bacteraemia in children admitted to a rural Mozambican hospital. Trop Med Int Health 14, 1011-1019 (2009).
58. Aide, P. et al. Four year immunogenicity of the RTS, S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine 29, 6059-6067 (2011).
59. RTS, S.C.T.P. Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31-45 (2015).
60. Bryan, D. et al. The establishment of a WHO Reference Reagent for anti-malaria (Plasmodium falciparum) human serum. Malar J 16, 314 (2017).
61. Vidal, M., Aguilar, M., Campo, J. J. & Dobaño, C. Development of quantitative suspension array assays for six immunoglobulin isotypes and subclasses to multiple Plasmodium falciparum antigens. Journal of Immunological Methods in press (2018).
62. Sanz, H. et al. drLumi: Multiplex Immunoassays Data Analysis. R package version 0.1.2. R package version 0.1.2 (2015).
63. Armbruster, D. A., Tillman, M. D. & Hubbs, L. M. Limit of detection (LQD)/limit of quantitation (LOQ): comparison of the empirical and the statistical methods exemplified with GC-MS assays of abused drugs. Clin Chem 40, 1233-1238 (1994).